Provenance Wealth Advisors’s Biogen BIIB Stock Holding History

Provenance Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500	Closed	-$76.5K	–	544
2024 Q4	$76.5K	Hold	500	–	–	0.01%	202
2024 Q3	$96.9K	Hold	500	–	–	0.01%	192
2024 Q2	$116K	Hold	500	–	–	0.02%	166
2024 Q1	$108K	Hold	500	–	–	0.02%	177
2023 Q4	$129K	Hold	500	–	–	0.02%	149
2023 Q3	$129K	Buy	+500	New	+$134K	0.02%	138

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Provenance Wealth Advisors's BIIB Position: Q1 2025 in Review

Provenance Wealth Advisors sold out of Biogen (BIIB) in Q1 2025, closing a stake of 500 shares — an estimated $76.5K sold.

Provenance Wealth Advisors first reported a position in BIIB in Q3 2023 and held it in 6 quarters. The position peaked at $129K in Q4 2023. 883 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

Provenance Wealth Advisors reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
Provenance Wealth Advisors sold 500 Biogen shares in Q1 2025, an estimated $76.5K.
Provenance Wealth Advisors first reported a position in Biogen in Q3 2023 and held it in 6 quarters.
Provenance Wealth Advisors's Biogen position peaked at $129K in Q4 2023.
883 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Provenance Wealth Advisors's 13F filing for Q1 2025, filed 15 Aug 2025.